Risk of gastrointestinal and hepatic toxicities in patients with cancer treated with regorafenib: A systematic review and meta- analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e22118
Abstract: e22118Background: Regorafenib is an oral small molecule inhibitor of multiple tyrosine kinases, including VEGFR, KIT, RET, RAF1, BRAF as well as PDGFR and FGFR, and is proven to be beneficial in di... read more here.
Keywords: toxicities patients; patients cancer; gastrointestinal hepatic; hepatic toxicities ... See more keywords
Association between Genetic Polymorphism of GSTP1 and Toxicities in Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15040439
Abstract: Platinum-based chemotherapy regimens have been proven to be effective in various cancers; however, considerable toxicities may develop and can even lead to treatment discontinuation. Diverse factors may influence adverse treatment events, with pharmacogenetic variations being… read more here.
Keywords: based chemotherapy; toxicities patients; polymorphism; platinum based ... See more keywords